Study of FK788 in Subjects With Chronic Hepatitis C Virus Infection
Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of 4
weeks therapy with FK788 in subjects with chronic hepatitis C virus (HCV) infection. Also, to
assess the effect of FK788 on serum ALT concentration and hepatitis C viral level during
therapy and for four weeks following therapy.